List view / Grid view
29 October 2013 | By GlaxoSmithKline
GSK and BMGF will invest a combined $1.8 million in early stage research into vaccine thermostability...
29 October 2013 | By Merck
“We are encouraged by these initial responses in NSCLC patients..."
29 October 2013 | By Boehringer Ingelheim
“Exercise is an essential component of COPD management..."
28 October 2013 | By Bristol-Myers Squibb
“Fibs or Facts” educational program launches today to help raise up to $25,000 for National Stroke Association...
28 October 2013 | By Bristol-Myers Squibb Company
Clazakizumab is a humanized anti-IL-6 monoclonal antibody directed against the IL-6 cytokine rather than the receptor...
28 October 2013 | By Boehringer Ingelheim
'Lung Cancer: We're Listening' will gather much needed feedback from individuals touched by lung cancer...
28 October 2013 | By Johnson & Johnson
Nearly 70 percent of patients receiving SIMPONI ARIA at two years demonstrated ACR 20 response...
28 October 2013 | By Johnson & Johnson
Breakthrough technology in ultrasonic energy designed to improve surgeon confidence in vessel sealing...
28 October 2013 | By Bristol-Myers Squibb Company
Clazakizumab is a humanized anti-IL-6 monoclonal antibody that is directed against the IL-6 cytokine...
27 October 2013 | By Boehringer Ingelheim
"The new sub-analysis confirms the consistent safety profile of afatinib in Asian patients..."
26 October 2013 | By Just:: Health Communications
“These data show that RoActemra can continue to deliver meaningful improvements for people living with rheumatoid arthritis..."
25 October 2013 | By GlaxoSmithKline
"GSK has a vibrant and growing business in Brazil and we are delighted to announce our support for the new sustainable chemistry centre..."
25 October 2013 | By Abbott
"With the MitraClip system, heart teams now have a catheter-based, less-invasive treatment option..."
24 October 2013 | By Johnson & Johnson
Antiviral Drugs Advisory Committee of the U.S. Food and Drug Administration voted unanimously to recommend approval of the investigational protease inhibitor simeprevir...
24 October 2013 | By Merck
The study evaluated the efficacy, immunogenicity and safety of V503 in females 16-26 years of age...
